Inactive Instrument

Alder BioPharmaceuticals, Inc.

Equities

US0143391052

Biotechnology & Medical Research

Alder BioPharmaceuticals, Inc. announced that it has received $99.999952 million in funding from Redmile Group, LLC

January 11, 2018

On January 12, 2018, Alder BioPharmaceuticals, Inc. closed the transaction. The company issued 725,268 class A-1 preferred stock at $137.88 per share for gross proceeds of $99,999,951.84. Preferred dividends accrue and accumulate semi-annually commencing on January 12, 2018 and are payable semi-annually in arrears on June 30 and December 31 of each year commencing on June 30, 2018.

Latest news about Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc. Announces Board Changes	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Biotechnology Select Industry Index	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P Global BMI Index	19-10-22	CI
Alder BioPharmaceuticals, Inc.(NasdaqGM:ALDR) dropped from S&P TMI Index	19-10-22	CI
H. Lundbeck A/S completed the acquisition of Alder BioPharmaceuticals, Inc..	19-10-21	CI
Alder BioPharmaceuticals, Inc. Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine	19-10-10	CI
H Lundbeck : Lundbeck buys Alder in $2 billion migraine treatment move	19-09-16	RE
H. Lundbeck A/S signed a Letter of Intent to acquire Alder BioPharmaceuticals, Inc. for $1.5 billion.	19-09-15	CI
Transcript : Alder BioPharmaceuticals, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-10-2019 02:55 PM	19-09-10
Transcript : Alder BioPharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019	19-08-06
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-06	CI
Alder BioPharmaceuticals, Inc. Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention	19-07-11	CI
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting	19-07-08	CI
Transcript : Alder BioPharmaceuticals, Inc. - Analyst/Investor Day	19-06-26
Transcript : Alder BioPharmaceuticals, Inc. Presents at UBS Global Healthcare Conference 2019, May-22-2019 10:00 AM	19-05-22
Alder Biopharmaceuticals, Inc. Announces New Analysis of Patient-Report Outcomes Data from the Promise-2 Phase 3 Clinical Trial of Eptinezumab	19-05-08	CI
Alder BioPharmaceuticals, Inc. Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention	19-05-08	CI
Alder BioPharmaceuticals Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine Across Four Clinical Trials	19-05-06	CI
Transcript : Alder BioPharmaceuticals, Inc., Q1 2019 Earnings Call, May 02, 2019	19-05-02
Alder Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-02	CI
Alder Biopharmaceuticals, Inc. Announces Resignation of Deepika R. Pakianathan as Class II Director	19-04-30	CI
Certain Stock Options of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Certain Restricted Stock Units of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Certain Class A-1 Convertible Preferred Stock of Alder BioPharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 29-APR-2019.	19-04-28	CI
Alder Biopharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting	19-04-23	CI

Chart Alder BioPharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+17.92%	126B
REGENERON PHARMACEUTICALS, INC.	+22.78%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.66%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-15.90%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.51%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.78%	14.08B

Bio Therapeutic Drugs